scispace - formally typeset
A

Augusto Afonso Guerra Junior

Researcher at Universidade Federal de Minas Gerais

Publications -  101
Citations -  1928

Augusto Afonso Guerra Junior is an academic researcher from Universidade Federal de Minas Gerais. The author has contributed to research in topics: Insulin glargine & Health services research. The author has an hindex of 21, co-authored 97 publications receiving 1458 citations. Previous affiliations of Augusto Afonso Guerra Junior include Pontifícia Universidade Católica de Campinas & Universidade Federal de Santa Catarina.

Papers
More filters
Journal ArticleDOI

Are new models needed to optimize the utilization of new medicines to sustain healthcare systems

TL;DR: The objective is to review case histories among health authorities to improve the utilization and expenditure on new medicines, as well as develop exemplar models for valuing medicines for orphan diseases alongside potentially capping pharmaceutical expenditure.
Journal ArticleDOI

Perfil epidemiológico dos pacientes em terapia renal substitutiva no Brasil, 2000-2004

TL;DR: El riesgo de mortalidad estuvo asociado with el aumento de la edad, sexo femenino, tener diabetes, residir en la region Norte y Noreste, dialisis peritoneal como modalidad de entrada y no haber realizado transplante renal.
Journal ArticleDOI

Disponibilidade de medicamentos essenciais em duas regiões de Minas Gerais, Brasil

TL;DR: A disponibilidade de medicamento tracador foi verificada no momento da visita e ao longo dos 12 meses imediatamente anteriores a pesquisa de campo, indicam a necessidade of divulgar e implementar o conceito de essencialidade no pais.
Journal ArticleDOI

Insulin Glargine in a Brazilian State: Should the Government Disinvest? an Assessment Based on a Systematic Review

TL;DR: This systematic review showed no therapeutic benefit of insulin glargine over other insulin formulations studied when analysing together glycaemic control and the frequency and severity of hypoglycaemia, and recommended to the State Authority to delist insulinglargine or renegotiate a price reduction with the manufacturer.